gentamicin C1a sulfate | 37713-04-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: gentamicin C1a sulfate
• 英文别名: (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid
• CAS: 37713-04-5
• 化学式: C₁₉H₃₉N₅O₇*(x)H₂O₄S
• 分子量: 547.6
• InChiKey: HNCAOLPMSASREN-UCMBPTNBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.63
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  297
• 氢给体数：
  10
• 氢受体数：
  16

反应信息

• 作为反应物：
  描述：

  gentamicin C1a sulfate 、 三苯基氯甲烷 在 三乙胺 作用下， 以 甲醇 、 水 、 氯仿 为溶剂， 生成
  参考文献：
  名称：

  WO2023/183628

  摘要：

  公开号：
• 作为产物：
  描述：

  庆大霉素 在 硫酸 作用下， 以 水 为溶剂， 生成 gentamicin C1a sulfate
  参考文献：
  名称：

  Structure–toxicity relationship of aminoglycosides: Correlation of 2′-amine basicity with acute toxicity in pseudo-disaccharide scaffolds

  摘要：

  A new pseudo-disaccharide NB23 with a 3',4'-methylidene protection was designed and its properties were evaluated in comparison to other two structurally related pseudo-disaccharides. The basicity of the 2'-amine was found to be well correlated to acute toxicity data in mice: the increase in the basicity is associated with the toxicity increase. Based on these data, a new pseudo-trisaccharide NB45 was constructed. NB45 exhibited significant antibacterial activity while at the same time retained low acute toxicity. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.08.053

文献信息

• Self-cleaving ribozymes and uses thereof
  申请人：Children's Medical Center Corporation

  公开号：EP2476707A1

  公开（公告）日：2012-07-18

  In certain embodiment, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.

  在某些实施方案中，本公开涉及与在哺乳动物细胞中发挥作用的基于核糖酶的基因调控系统有关的组合物和方法。在某些具体的实施方案中，本公开涉及血吸虫自裂解 RNA 突变模板。
• SELF-CLEAVING RIBOZYMES AND USES THEREOF
  申请人：Children's Medical Center Corporation

  公开号：EP3279328A1

  公开（公告）日：2018-02-07

  In certain embodiment, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs.

  在某些实施方案中，本公开涉及与在哺乳动物细胞中发挥作用的基于核糖酶的基因调控系统有关的组合物和方法。在某些具体的实施方案中，本公开涉及血吸虫自裂解 RNA 突变模板。
• Use of an aminoglycoside for nonsense mutation suppression and the treatment of disease
  申请人：PTC Therapeutics, Inc.

  公开号：US10555960B2

  公开（公告）日：2020-02-11

  Methods of using and pharmaceutical compositions comprising (2R,3S,4R,5R,6S)-5-amino-6-(((1R,2S,3S,4R,6S)-4,6-diamino-3-(((2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)tetrahydro-2H-pyran-2- yl)oxy)-2-hydroxycyclohexyl)oxy)-2-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol are disclosed, including methods of treating or preventing a nonsense mutation mediated disease associated with premature translation termination or a premature stop codon resulting from a germline or somatic nonsense mutation.

  使用包含(2R,3S,4R,5R,6S)-5-氨基-6-(((1R,2S,3S,4R,6S)-4,6-二氨基-3-(((2R,3R,4R、5R)-3,5-二羟基-5-甲基-4-(甲基氨基)四氢-2H-吡喃-2-基)氧基)-2-羟基环己基)氧基)-2-(羟甲基)四氢-2H-吡喃-3、4-二醇的方法，包括治疗或预防无义突变介导的、与种系或体细胞无义突变导致的过早翻译终止或过早终止密码子有关的疾病的方法。
• USE OF AN AMINOGLYCOSIDE FOR NONSENSE MUTATION SUPPRESSION AND THE TREATMENT OF DISEASE
  申请人：PTC Therapeutics, Inc.

  公开号：US20180147228A1

  公开（公告）日：2018-05-31

  Methods of using and pharmaceutical compositions comprising (2R,3S,4R,5R,6S)-5-amino-6-(((1R,2S,3S,4R,6S)-4,6-diamino-3-(((2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)tetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)- 2-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol are disclosed, including methods of treating or preventing a nonsense mutation mediated disease associated with premature translation termination or a premature stop codon resulting from a germline or somatic nonsense mutation.
• US4695536A
  申请人：——

  公开号：US4695536A

  公开（公告）日：1987-09-22